GSK-3494245 is under clinical development by GSK and currently in Phase I for Leishmaniasis (Kala-Azar). According to GlobalData, Phase I drugs for Leishmaniasis (Kala-Azar) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GSK-3494245’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GSK-3494245 overview
GSK-3494245 is under development for the treatment of leishmaniasis. GSK-3494245 acts by targeting proteasome. It is administered through oral route.
For a complete picture of GSK-3494245’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.